01—Abstract
Summary
Summary of the 8-K filed August 5, 2026. Cited figures are marked; the original filing is the authoritative source.
BeOne Medicines (NASDAQ: ONC) reported strong second-quarter 2026 results, with total revenue of $1.705 billiona, up 30% year over year, driven primarily by BRUKINSA (global sales of $1.2 billion, up 31%; U.S. sales of $893 million, up 31%).
Product gross margin expanded to 90% from 87%, reflecting higher BRUKINSA mix and productivity gains. GAAP operating income rose to $325 millionb from $88 million, and GAAP net income reached $237 million (diluted EPS of $2.05 per ADS) versus $94 million a year earlier. Free cash flow was $435 million, up 98%, and cash, cash equivalents and restricted cash rose to $5.28 billion at June 30, 2026.
Operating expenses grew 13% on a GAAP basis, but SG&A fell to 35% of product sales from 41%, indicating operating leverage. Management raised full-year 2026 guidance: total revenue to $6.6c-6.8 billion (from $6.3-6.5 billion), GAAP operating income to $1.0-1.1 billion (from $750-850 million), and non-GAAP operating income to $1.7-1.8 billion (from $1.45-1.55 billion). The company also flagged a possible material income tax benefit from reversing valuation allowances in 2026, though timing and magnitude are uncertain.
This tax item could meaningfully boost reported GAAP net income and EPS in a future period, so investors should separate it from operating performance. Key near-term catalysts include 2H 2026 regulatory submissions for BRUKINSA in first-line mantle cell lymphoma, FDA action on TEVIMBRA plus ZIIHERA in first-line HER2-positive gastroesophageal adenocarcinoma, and several pipeline milestones. Note that the 2Q GAAP results include a $49.8 milliond discrete tax benefit, and that non-GAAP figures exclude share-based compensation and depreciation.
Leverage also rose: debt increased to $1.07 billion and interest expense reached $40 million in the quarter, and the Royalty Pharma arrangement continues to affect other expense. The press release figures are unaudited.
02—Key points
Key Highlights
- Total revenue of $1.705 billion, up 30% year over year; BRUKINSA global sales of $1.2 billion, up 31%, with U.S. BRUKINSA sales of $893 million.
- GAAP operating income of $325 million (vs. $88 million) and GAAP diluted EPS of $2.05 per ADS (vs. $0.84); non-GAAP diluted EPS of $3.84 per ADS (vs. $2.25).
- Gross margin on product sales expanded to 90% from 87%, driven by higher BRUKINSA mix and lower production costs for BRUKINSA and TEVIMBRA.
- Free cash flow of $435 million, up 98%; operating cash flow of $463 million in the quarter, and cash and equivalents of $5.28 billion at June 30, 2026.
- Full-year 2026 guidance raised: total revenue $6.6-6.8 billion, GAAP operating income $1.0-1.1 billion, non-GAAP operating income $1.7-1.8 billion.
- Potential material income tax benefit from reversal of valuation allowances in 2026; timing and size are uncertain and could significantly lift reported GAAP net income.
- Pipeline catalysts in 2H 2026 include BRUKINSA first-line MCL regulatory submissions, FDA action on TEVIMBRA plus ZIIHERA in first-line HER2+ GEA, and tacabrutideg Phase 2 submission consideration.
03—Questions
Frequently Asked Questions
What drove the revenue growth in the second quarter of 2026?
Growth was driven mainly by BRUKINSA, with global sales of $1.2 billion (up 31%) and U.S. sales of $893 million (up 31%). TEVIMBRA sales rose 18% to $229 million, and Amgen in-licensed products grew 25% to $157 million.
Why did GAAP operating income and margins improve so much?
Revenue grew faster than costs. Product gross margin rose to 90% from 87% on a richer BRUKINSA mix and productivity gains. SG&A fell to 35% of product sales from 41%, even though total GAAP operating expenses rose 13%.
What is the potential impact of the income tax valuation allowance reversal?
Management said earnings may provide enough positive evidence to reverse certain valuation allowances in 2026, which would produce a material one-time tax benefit. The timing and amount are uncertain, and this benefit would inflate GAAP net income and EPS in the period it is recognized, so it should be viewed separately from operating performance.
How did the guidance change, and what does it imply?
Full-year 2026 revenue guidance rose to $6.6-6.8 billion from $6.3-6.5 billion, and GAAP operating income guidance rose to $1.0-1.1 billion from $750-850 million. The company also expects about 118 million diluted ADSs outstanding and other expense of $25-50 million, including Royalty Pharma interest amortization. Guidance excludes any new business development deals.
Are there any balance sheet or leverage concerns?
Debt increased to $1.07 billion from $1.02 billion at year-end 2025, and quarterly interest expense was $40 million, up from $8 million a year earlier. The $906 million sale of future royalty liability is also a significant obligation. Cash of $5.28 billion and positive free cash flow offset these obligations, but investors should monitor the cost and growth of the company's debt and royalty commitments.
04—Continue